Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Dr Hammers on the Efficacy of IO/TKI and IO/IO Regimens in ccRCC

July 18th 2025

Hans Hammers, MD, PhD, discusses the main efficacy differences between IO/TKI and IO/IO combinations in clear-cell renal cell carcinoma.

Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC

July 18th 2025

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

High Levels of CD163+ Tumor-Associated Macrophages Could Improve Outcomes With Nivolumab in Metastatic RCC

July 18th 2025

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.

KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC

July 18th 2025

KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.

Dr Kotecha on the Potential of ENPP3 as a Therapeutic Target in ccRCC

July 18th 2025

Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.

Pembrolizumab/Lenvatinib Combination Produces Durable Responses in Advanced Non–Clear Cell RCC

July 18th 2025

Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Dr Sfakianos on Outcomes With Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC

July 18th 2025

John Sfakianos, MD, shared findings from an analysis of mitomycin intravesical solution from the phase 3 ENVISION trial in recurrent NMIBC.

Metastasis-Directed Radiotherapy Yields Durable Disease Control Without Systemic Therapy in Oligometastatic RCC

July 18th 2025

Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

Dr Powles on Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC

July 17th 2025

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Dr Machaalani on the Potential Role of Circulating KIM-1 as a Biomarker in Metastatic RCC

July 17th 2025

Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.

Investigational Neoantigen Vaccines Target RCC Mutations and Drive Durable T-Cell Activity

July 17th 2025

David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.

Novel CAR T-Cell Therapy Could Pave the Way for Improvements in Advanced ccRCC Management

July 17th 2025

Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.

Dr Martini on the Evolving Role of Intravesical Therapies in High-Risk NMIBC

July 16th 2025

Alberto Martini, MD, discusses the evolving role of intravesical therapies in patients with high-risk non–muscle-invasive bladder cancer.

Long-Term Follow-Up Data With IO/IO and IO/TKI Combinations Better Inform Clinical Decision-Making in Advanced ccRCC

July 16th 2025

Hans Hammers, MD, PhD, discusses the efficacy, safety, and clinical utilization of IO/IO and IO/TKI combinations in advanced clear-cell RCC.

Classification Advances Guide Research and Precision Therapy in Non–Clear Cell RCC

July 16th 2025

Joseph Vento, MD, discusses how WHO updates and molecular profiling are shaping trial design and targeted treatment in non–clear cell RCC.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Dr Chehrazi-Raffle on Tivozanib With/Without Nivolumab in Metastatic RCC

July 9th 2025

Alexander Chehrazi-Raffle, MD, discusses findings from an exploratory analysis of the TiNivo-2 trial of tivozanib with/without nivolumab in metastatic RCC.

Dr Haas on the Safety Profile of Adjuvant Pembrolizumab in Clear Cell RCC

July 8th 2025

Naomi B. Haas, MD, discusses safety data from the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Low KIM-1 Levels Are Associated With Improved Clinical Outcomes in Advanced RCC

July 2nd 2025

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.